Opinion|Videos|December 10, 2024

Vowst as a Potential Option for Patients With Recurrent C Difficile Infections

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut bacteria to restore microbiome diversity, distinguishing itself from traditional antibiotics in preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment.

Video content above is prompted by the following:

  • What is the mechanism of action of Vowst, and how does this therapy differ from previously used therapies in recurrent C difficile infections?
  • What is the key data that led to the FDA-approval of Vowst for recurrent C difficile infection?
  • Who are the target patient populations for Vowst?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo